Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RPA1 | P27694 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13157576 | 0.93 | MGLL (0.45) | MGLLMALT1PTGS2KDM1A | |
| SCHEMBL3104707 | 0.93 | MGLL (0.54) | MGLLMALT1PTGS2RPA1 | |
| SCHEMBL3105667 | 0.93 | MGLL (0.54) | MGLLMALT1PTGS2RPA1 | |
| SCHEMBL3105238 | 0.91 | KDM1A (0.46) | MGLLMALT1PTGS2KDM1A | |
| SCHEMBL3100407 | 0.88 | PTGS2 (0.50) | MGLLMALT1PTGS2RPA1 | |
| SCHEMBL13157595 | 0.88 | MGLL (0.51) | MGLLMALT1FAAHRPA1 | |
| SCHEMBL3104741 | 0.85 | CCKAR (0.47) | PTGS2 | |
| SCHEMBL13157636 | 0.84 | PTGS2 (0.58) | MALT1PTGS2 | |
| SCHEMBL13157631 | 0.84 | PTGS2 (0.48) | MGLLMALT1PTGS2RPA1KDM1A | |
| SCHEMBL13157600 | 0.84 | PTGS2 (0.58) | MALT1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2009006-A1 | UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | TORAY INDUSTRIES, INC. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | MGLL 1894/4885MALT1 4787/4885FAAH 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.